UpdatesPlus: In depth analysis of breaking R&D

Are you looking for rapid analysis of breaking R&D activity that will impact on your drug development or marketing activity? If you are UpdatesPlus is for you.

In depth analysis of breaking research:LeadDiscovery already delivers DailyUpdates one of the most popular alert services in the pharmabiotech sector. Based on this proven track record of identifying key R&D activity our industrial panel now offers, through UpdatesPlus, analysis of its importance.

Delivered monthly in an easy to read presentation-ready format:UpdatesPlus has been designed to deliver analysis with clarity characteristic of LeadDiscovery products. Delivered monthly in PowerPoint format, UpdatesPlus is designed to be succinct, easy to read, and simple to convert for the purposes of monthly internal meetings.

UpdatesPlus is now available for:
  • Nicotinic Receptors
  • Addictive Disorders
  • Lupus
  • IBD
  • Psoriasis
  • Rheumatoid Arthritis

For free samples please contact fiona.watts@leaddiscovery.co.uk

Does this work support a new molecular target? Are we looking at a potential licensing opportunity? Are our competitors advancing their pipeline or has their lead just crashed? These are just some of the questions answered in UpdatesPlus

Information sources: UpdatesPlus focuses on material featured over the previous 4 weeks in DailyUpdates as well as in additional sources. Sources include: Journal articles; Press releases; Clinical Trial databases; Company websites; Proprietary R&D databases; Investor presentations; Key scientific conferences.

Focus: UpdatesPlus is client led. If you have an area that needs to be tracked let us know. UpdatesPlus is suited to covering multiple indications for a single molecular target or multiple molecular targets for a single indication

Cost & Delivery: UpdatesPlus is priced to reflect the size of the area covered. The service can be priced on an exclusive (just your company) or non-exclusive basis. In either case UpdatesPlus is available on a company wide license.